Scalper1 News
Big biotech Amgen (AMGN) was trading up Friday after it announced a cancer collaboration with Merck (MRK) and filed for its first biosimilar approval, despite a tepid initiation report from Wells Fargo. Amgen and Merck said that they are launching a study combining Merck’s Keytruda, which is currently used to treat melanoma and non-small-cell lung cancer, with Amgen’s leukemia drug Blincyto, in a study of patients with diffuse large B-cell Scalper1 News
Scalper1 News